Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR-1: Salanersen in Presymptomatic Infants With SMA
NCT07221669Phase 3Recruiting
- Sponsor
- Biogen
- Start
- Apr 2026
- Primary completion
- Nov 2028
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of salanersen in spinal muscular atrophy (SMA), sponsored by Biogen. Primary endpoints: Percentage of Participants with 2 SMN2 Copies Sitting Without Support (for at Least 10 Seconds) at 12 months, Percentage of Participants with 3 SMN2 Copies Walking Alone (for at Least 5 Steps) at 18 months and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
salanersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT07221669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221669.